TransMedics Group Inc (TMDX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
TransMedics Group Inc stock (TMDX) is currently trading at $108.92. TransMedics Group Inc PE ratio is 22.37. TransMedics Group Inc PS ratio (Price-to-Sales) is 6.17. Analyst consensus price target for TMDX is $161.30. WallStSmart rates TMDX as Hold.
- TMDX PE ratio analysis and historical PE chart
- TMDX PS ratio (Price-to-Sales) history and trend
- TMDX intrinsic value — DCF, Graham Number, EPV models
- TMDX stock price prediction 2025 2026 2027 2028 2029 2030
- TMDX fair value vs current price
- TMDX insider transactions and insider buying
- Is TMDX undervalued or overvalued?
- TransMedics Group Inc financial analysis — revenue, earnings, cash flow
- TMDX Piotroski F-Score and Altman Z-Score
- TMDX analyst price target and Smart Rating
TransMedics Group Inc
📊 No data available
Try selecting a different time range
TMDX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · TransMedics Group Inc (TMDX)
TMDX trades at a significant discount to its Graham intrinsic value of $227.92, offering a 42% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
TransMedics Group Inc (TMDX) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, revenue growth, eps growth. Concerns around price/book. Fundamentals are solid but monitor weak areas for improvement.
TransMedics Group Inc (TMDX) Key Strengths (6)
Every $100 of shareholder equity generates $54 in profit
Revenue surging 32.20% year-over-year
Earnings per share surging 1188.00% year-over-year
Keeps $31 of every $100 in revenue as net profit
111.30% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
TransMedics Group Inc (TMDX) Areas to Watch (3)
Very expensive at 8.3x book value
Thin operating margins with cost pressures present
Premium valuation at 6.2x annual revenue
Supporting Valuation Data
TransMedics Group Inc (TMDX) Detailed Analysis Report
Overall Assessment
This company scores 64/100 in our Smart Analysis, earning a C+ grade. Out of 9 metrics analyzed, 6 register as strengths (avg 9.5/10) while 3 fall into concern territory (avg 3.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Revenue Growth, EPS Growth. Profitability is solid with Return on Equity at 54.20%, Profit Margin at 31.40%. Growth metrics are encouraging with Revenue Growth at 32.20%, EPS Growth at 1188.00%.
The Bear Case
The primary concerns are Price/Book, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (6.17), Price/Book (8.26) suggest expensive pricing. Profitability pressure is visible in Operating Margin at 13.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 54.20% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 32.20% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, Revenue Growth) and negatives (Price/Book, Operating Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TMDX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TMDX's Price-to-Sales ratio of 6.17x trades at a deep discount to its historical average of 26.88x (3th percentile). The current valuation is 92% below its historical high of 76.11x set in Jun 2019, and 18% above its historical low of 5.23x in Jan 2025. Over the past 12 months, the PS ratio has expanded from ~5.3x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for TransMedics Group Inc (TMDX) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
TransMedics Group Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 605M with 32% growth year-over-year. Profit margins are strong at 31.4%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 32% YoY, reaching 605M. This pace significantly outperforms most MEDICAL DEVICES peers.
ROE of 5420.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can TransMedics Group Inc maintain 32%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.96, so expect amplified moves relative to the broader market.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact TransMedics Group Inc.
Bottom Line
TransMedics Group Inc offers an attractive blend of growth (32% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(16 last 3 months)
| Insider | Type | Shares |
|---|---|---|
CORCORAN, NICHOLAS See remarks | Sell | -984 |
Data sourced from SEC Form 4 filings
Last updated: 8:27:07 AM
About TransMedics Group Inc(TMDX)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
TransMedics Group, Inc., a commercial-stage medical technology company, is dedicated to transforming organ transplant therapy for patients with end-stage organ failure in the United States and internationally. The company is headquartered in Andover, Massachusetts.